Serum creatinine changes in HIV-seropositive patients receiving tenofovir [3]

AIDS

Volumn 20, Issue 5, 2006, Pages 786-787

  El Sahly, Hana M ^a   Teeter, Larry ^a   Zerai, Teddy ^b   Andrade, Roberto A ^a   Munoz, Cesar ^b   Nnabuife, Calista ^b   Hunter, Rodney ^c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b HARRIS COUNTY HOSPITAL DISTRICT   (United States)

^c TEXAS SOUTHERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR DISOPROXIL;

COMORBIDITY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DATA ANALYSIS; DIABETES MELLITUS; DRUG EFFICACY; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; INFORMATION PROCESSING; KIDNEY FAILURE; KIDNEY FUNCTION; LETTER; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MEDICAL RECORD; NEPHROTOXICITY; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; WEIGHT GAIN;

ADENINE; CREATININE; CROSS-SECTIONAL STUDIES; HIV INFECTIONS; HUMANS; KIDNEY FAILURE, ACUTE; PHOSPHONIC ACIDS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 33745113205     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000216386.60481.47     Document Type: Letter

References (5)

1. Fung HB, Stone EA, Pianceti FJ. Tenofovir disoproxil fumarate: a nucleotide reverse transcriptase inhibitor for the treatment if HIV infection. Clin Ther 2002; 242:1515-1548.
2. Peyriere H, Reynes J, Rouanet I, Daniel N, de Boever CM, Mauboussin JM, et al. Renal tubular dysfunction associated with tenofovir therapy - report of 7 cases. J Acquir Immune Defic Syndr 2004; 35:269-273.
3. Jones R, Stebbing J, Nelson M, Moyle G, Bower M, Mandalia S, Gazzard B. Renal dysfunction with tenofovir disoprooxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently. J Acquir Immune Defic Syndr 2004; 37:1489-1495.
4. Izzedine H, Hulot JS, Vittecoq, Gallant JE, Staszewski S, Launay-Vacher V, et al. Long term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study. Nephrol Dial Transplant 2005; 20:743-746.
5. Gallant JE, Parish ME, Keruly JC, Moore RD. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis 2005; 40:1194-1198.